SCHEMBL6320945

SCHEMBL6320945

Cc1ccc(CNC(=O)c2c(-c3ccc(C)s3)noc2N)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.49
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
KDM4E B2RXH2 1/20 0.43
TP53 P04637 4/20 0.43
LMNA P02545 3/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA7 P43166 1/20 0.42
GAA P10253 1/20 0.42
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 5/20 0.41
CHRM4 P08173 1/20 0.41
ATM Q13315 1/20 0.41
RXFP1 Q9HBX9 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317603 0.91 GAA (0.53) KMT2AALDH1A1GAAMEN1MAPT
SCHEMBL6315784 0.90 KMT2A (0.47) KMT2AALDH1A1HPGDKDM4ETP53
SCHEMBL6314978 0.90 KMT2A (0.47) KMT2AALDH1A1HPGDKDM4ETP53
SCHEMBL6316367 0.89 MAPT (0.52) KMT2AALDH1A1HPGDTP53LMNA
SCHEMBL6318905 0.86 CHRM4 (0.45) KMT2ALMNACA1CA2CA4
SCHEMBL6317710 0.84 KMT2A (0.47) KMT2AALDH1A1HPGDKDM4ELMNA
SCHEMBL6316269 0.84 GAA (0.59) KMT2AALDH1A1HPGDKDM4ETP53
SCHEMBL6315224 0.83 ADORA1 (0.48) KMT2AALDH1A1HPGDCA1CA2
SCHEMBL6316383 0.83 CHRM4 (0.48) KMT2AALDH1A1HPGDTP53LMNA
SCHEMBL6321669 0.83 TACR1 (0.48) ALDH1A1KDM4ECA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 KMT2A 1089/4885ALDH1A1 4444/4885HPGD 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.